Melinda Magyari, MD, PhD, The Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, discusses the post-authorization safety study that assessed risks of adverse events of special interest (AESI) associated with teriflunomide, a disease-modifying therapy indicated for the treatment of remitting-relapsing forms of multiple sclerosis (MS). The study was based on secondary use of individual data of patients from various registries and found no evidence that teriflunomide use was associated with an increased risk of AESI. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.